Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Plan

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 12,500 shares of common stock at an average price of $20.606 per share on March 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 19, 2025, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold 12,500 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• The shares were sold at a weighted average price of $20.606, with individual transactions ranging from $20.23 to $21.16.
• Following the transaction, Lyssikatos directly owns no shares but indirectly owns 1,002,688 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of an insider stock sale under a pre-arranged trading plan. There's no indication of positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sale is unusually large or coincides with other significant news.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies.
• The use of 10b5-1 trading plans is a standard practice among executives to manage their stock holdings and avoid potential conflicts of interest.
• Comparable companies such as Relay Therapeutics, Black Diamond Therapeutics, and Blueprint Medicines also have executives who utilize 10b5-1 plans for stock transactions.
• The size of this transaction (12,500 shares) is relatively small compared to the overall trading volume of Enliven Therapeutics and is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Joseph P. Lyssikatos, Chief Scientific Officer, Rule 10b5-1, Stock Sale, Beneficial Ownership